Pro Forma Financial Results Results excluding the impact of discontinuation of M6 product lines Net Sales by Major Product Category by Reporting Segment | | | | | Three Months Ended September | 30, | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | Constant | | | | | | | | Currency | | (Unaudited, U.S. Dollars, in millions) | | 2025 | | 2024 | Change | Change | | Bone Growth Therapies | $ | 61.2 | $ | 57.9 | 5.7% | 5.7% | | Spinal Implants, Biologics and Enabling Technologies* | | 108.6 | | 102.9 ...